<DOC>
	<DOC>NCT00309088</DOC>
	<brief_summary>The purpose of the study is to investigate the efficacy and safety for steroid non-resistant MG patients in a double blind, placebo controlled study.</brief_summary>
	<brief_title>FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients</brief_title>
	<detailed_description />
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Clinically diagnosed as myasthenia gravis Those whose MG symptoms are wellcontrolled by the treatment with prednisone Steroid nonrefractory Myasthenia Gravis: ≧20mg and ≦40mg / alternate day of steroid dose required to maintain Those who have thymoma or the history of thymoma (Masaoka stage III or IV) Patients who received steroid pulse therapy, plasma exchange therapy, globulin therapy or radiation therapy within 12 weeks prior to the initiation of test drug Patients who started the immunosuppressant therapy or increased the dose of immunosuppressant within 12 weeks prior to the initiation of test drug. Patients who had undergone thymectomy within 24 weeks prior to the initiation of test drug. Pancreatitis or diabetes Serum creatinine≦1.5mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Myasthenia Gravis</keyword>
</DOC>